Loading…
Employees: 1,936
Size MedicalSystem Biotechnology (300439.SZ) is a China Health Care company (Medical Specialties) with a market value of $556M, the 3603rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.65 on 6 Nov 2026.
Performance Over six months the shares fell 4.4%, against -13.5% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 14.4% over the last twelve months (peer median +4.2%); the operating margin is 2.2% (peer median 2.7%).
Valuation It trades at 1.7× enterprise value to sales against a peer median of 3.6× (5th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.7 points below its cost of capital (6.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.68B | CN¥1.53B | CN¥1.74B | CN¥1.88B | CN¥2.48B |
| Revenue growth | — | -12% | -7% | -24% | — |
| Gross profit | CN¥683M | CN¥496M | CN¥718M | CN¥767M | CN¥892M |
| EBITDA | n/a | CN¥180M | CN¥456M | CN¥437M | CN¥415M |
| Net income | CN¥101M | CN¥63.2M | CN¥258M | CN¥257M | CN¥199M |
| Free cash flow | CN¥30.4M | CN¥96.4M | -CN¥18.7M | CN¥383M | CN¥270M |
| Capital expenditure | CN¥153M | CN¥191M | CN¥421M | CN¥280M | CN¥303M |
| Total debt | CN¥112M | CN¥83.0M | CN¥89.9M | CN¥108M | CN¥352M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300439.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.1% | -3.3% | 9th lowest of 20 |
| 6-month return | -4.4% | -13.5% | 7th highest of 20 |
| Distance from 52-week high | -13.1% | -39.9% | highest of 20 |
| Revenue growth (TTM) | +14.4% | +4.2% | 5th highest of 20 |
| Operating margin | 2.2% | 2.7% | 10th lowest of 20 |
| EV / Sales | 1.7× | 3.6× | 5th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 7.4% | 10.1% | 5th least demanding of 12 |
| Growth delivered (Del g) | -7.8% | +5.0% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | +15.2 pp | +5.1 pp | 6th most demanding of 12 |
| ROIC minus cost of capital | -0.7 pp | -2.3 pp | 7th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 2.8× | 11.6% | +6.5% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 1.5× | 7.8% | +12.0% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 3.6× | 34.4% | +6.7% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | 6.3× | 17.3% | -19.8% |